ImmunoScape

ImmunoScape is a biotechnology company focused on transforming cancer therapy with our novel Seed-and-Boost approach.

[ImmunoScape @ImmunoScape]

We are proud to announce the execution of a MOU with a premier NCI-designated U.S. Comprehensive Cancer Center to fast-track our pipeline program. We are also super thrilled to welcome Leonardo DiCaprio as a strategic investor.
https://t.co/vB7tj9aUpE

[ImmunoScape @ImmunoScape]

ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies is thrilled and pleased to announced an exclusive in-licensing deal with Cue Biopharma.
https://t.co/89msRkS7sg

[ImmunoScape @ImmunoScape]

We are excited to announce a strategic collaboration and exclusive licensing agreement with Cue Biopharma to advance a novel in vivo T-cell expansion Seed-and-Boost approach for solid tumor therapy.
https://t.co/epAHZ5DHWp

[ImmunoScape @ImmunoScape]

ImmunoScape CEO Choon-Peng Ng will make two appearances on March 5 at BioCentury-BayHelix East-West Summit: Singapore, presenting on ImmunoScape in the morning and participating in an afternoon panel on how Asia will drive biotech’s golden age. Learn more: https://t.co/AEnzTSdtV0

[ImmunoScape @ImmunoScape]

On Wednesday, March 6 at 2:55 p.m. EST, ImmunoScape VP of Innovation Michael Fehlings, PhD, will participate in a panel discussion “AI for Therapeutics: Upstream Applications; Downstream Challenges.” Register here: https://t.co/cx12F8zpUQ

[ImmunoScape @ImmunoScape]

2023 was an exciting year at ImmunoScape, featuring transformative technical progress, new partnerships, expert additions to our leadership team and more. Read our 2023 Recap for a look back at the highlights, plus a preview of what’s on the way for 2024: https://t.co/VqNjjuwHvt

[ImmunoScape @ImmunoScape]

With EDDC, we aim to develop off-the-shelf TCR-based molecules to make these therapeutics more accessible to a much broader patient population at lower production costs and shorter timelines for the patients.
#machinelearning #therapeutics #immunotherapy
https://t.co/pM0wxFs23b

[ImmunoScape @ImmunoScape]

We are excited to work with the team at MiNK Therapeutics to fast track the development of next generation TCR-based therapies for solid tumors.

#machinelearning #therapeutics #immunotherapy

Learn more: https://t.co/Ol9c30fDox

[ImmunoScape @ImmunoScape]

ImmunoScape is using data-driven approaches to foster the discovery of novel and efficacious TCRs across a variety of tumor indications. Read how our diverse TCR portfolio generates opportunities beyond T cell engineering. #machinelearning #immunotherapy https://t.co/qd6FhUM2b8

[ImmunoScape @ImmunoScape]

If you're interested in meeting the ImmunoScape team at JP Morgan & to learn more about our progress on the development of novel TCR-based therapeutics using our Deep Immunomics platform, send us a message at [email protected]
#jpm2024 #immunotherapy #tcells #machinelearning

[ImmunoScape @ImmunoScape]

Ayesha Siddiqui from @AsiaBioSpectrum spoke with our CEO and Co-Founder Choon-Peng (Choon) Ng about the progress around cancer research in Asia for her recent piece. See what Choon had to say in the full piece: https://t.co/kukJZ8SzRN

#cancerresearch #apac #immunology

[ImmunoScape @ImmunoScape]

Our CEO and co-founder Choon-Peng Ng recently spoke with @AsiaBioSpectrum about how our Deep Immunomics & machine learning platforms can discover novel TCR-based therapeutics against a diverse range of tumor antigens: https://t.co/svyb247tRB #immunology #tcells

[ImmunoScape @ImmunoScape]

We are excited to attend the 41st Annual JPM Health Care Conference in San Francisco next week! Our CEO & VP of Discovery will be on-site January 9-10th.

If you're interested in setting up a meeting email us at [email protected] or send us a DM. #Immunology #JPM23

[ImmunoScape @ImmunoScape]

Are you attending the 41st Annual JPM Healthcare Conference in San Francisco next month? Our CEO & VP of Discovery will be on-site 1/9-1/10. If you're interested in setting up a meeting, DM us or email [email protected]. #JPM23 #Immunology

[ImmunoScape @ImmunoScape]

One of our senior scientists in discovery, Juliana Barclay, will be presenting at @sitcancer SITC 2022 in Boston this Friday, November 11: https://t.co/zsGbYRxwkK #immunology #tcells #SITC22

[ImmunoScape @ImmunoScape]

As ImmunoScape grows, we are hiring a Research Associate, Discovery in San Diego. For more information, please visit our careers page: https://t.co/QlhE0A5079
#wearegrowing #wearehiringnow #hiringtoday #joinourteam #hiring #biomedicaljobs #researchjobs #researchassociate

[ImmunoScape @ImmunoScape]

As ImmunoScape grows, we are hiring a Research Scientist, Technology Development in San Diego. For more information, please visit our careers page: https://t.co/ngRjRcE7kV
#wearehiringnow #hiringtoday #joinourteam #hiring #biomedicaljobs #researchjobs #researchscientist

[ImmunoScape @ImmunoScape]

As ImmunoScape grows, we are hiring a Director, Discovery in San Diego. For more information, please visit our careers page: https://t.co/iv31Aevd2e
#wearegrowing #wearehiringnow #hiringtoday #joinourteam #hiring #biomedicaljobs #researchjobs #director

[ImmunoScape @ImmunoScape]

One of our senior scientists in discovery, Juliana Barclay, will be presenting at @sitcancer 2022 in Boston on November 11. She will present on the discovery and development of t-cell receptors for adoptive t-cell therapy against solid tumors. https://t.co/qu8H8EAuaZ #SITC22

[CAR-TCR @CAR_TCell]

@ImmunoScape's Dan MacLeod in the Discovery track this morning: Discovery of TCRs Targeting Novel Antigens Using Deep Immunomics

#CARTCR #immunotherapy